Douglas B. Johnson MD, MSCI

Douglas B. Johnson, MD, MSCI, is Associate Professor of Medicine in the Department of Medicine at Vanderbilt University Medical Center. He is the Co-Leader of the Translational Research and Interventional Oncology Research Program and the Clinical Director of Melanoma at Vanderbilt-Ingram Cancer Center.

Dr. Johnson earned his medical degree from University of Alabama at Birmingham. He completed a residency at Duke University, and a fellowship and MSCI program at Vanderbilt.

Dr. Johnson’s primary scientific interests are in developing and understanding biomarkers for immune and targeted therapeutics and developing clinical trials for melanoma patients. He leads the melanoma clinical research program at Vanderbilt. His research interests cover a wide range of developing new immune and targeted therapies for melanoma, and in using existing treatments in the most effective ways. He is exploring ways to profile cancers to predict which patients will benefit from immune therapies, and has published numerous papers in this area. He is also focused on understanding the effectiveness and toxicities of immune therapies in high-risk patients, including those with autoimmune disorders, advanced age, or organ dysfunction. He is the lead investigator on numerous clinical trials at Vanderbilt.

Dr. Johnson currently serves as Vice-Chair of the NCCN Melanoma Panel. He was an NCCN Young Investigator Award recipient, and currently serves on the YIA Proposal Review Committee.